+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Amyloid and Tau Positron Emission Tomography in Suggested Diabetesrelated Dementia

Amyloid and Tau Positron Emission Tomography in Suggested Diabetesrelated Dementia

Current Alzheimer Research 15(11): 1062-1069

Type 2 diabetes mellitus (DM) has been shown to increase the risk for cognitive decline and dementia, such as Alzheimer disease (AD) and vascular dementia (VaD). In addition to AD and VaD, there may be a dementia subgroup associated with specific DM-related metabolic abnormalities rather than AD pathology or cerebrovascular disease, referred to as diabetes-related dementia (DrD). We studied 11C-PiB and 11C-PBB3 positron emission tomography (PET) in 31 subjects with DrD and 5 subjects with AD associated with DM to assess amyloid and tau deposits in the brain. All subjects with AD showed both positive PiB and PBB3. However, only 12 out of 31 subjects (39%) with DrD showed positive PiB, whereas 17 out of 21 subjects (81%) who underwent PBB3 PET showed positive PBB3. Depending on the positivity of PiB and PBB3, we classified 21 subjects into a negative PiB and a positive PBB3 pattern (11 cases, 52%), indicating tauopathy, a positive PiB and a positive PBB3 pattern (6 cases, 29%), indicating AD pathology, or a negative PiB and a negative PBB3 pattern (4 cases, 19%). Among 11 subjects showing a negative PiB and a positive PBB3 pattern, there were 2 PBB3 deposit patterns, including the medial temporal lobe only and extensive neocortex beyond the medial temporal lobe. DrD showed variable amyloid and tau accumulation patterns in the brain. DrD may be associated predominantly with tau pathology, in addition to AD pathology and non-amyloid/non-tau neuronal damage due to DM-related metabolic abnormalities.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 046508116

Download citation: RISBibTeXText

PMID: 29984653

Related references

Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography. Movement Disorders 24(Suppl. 2): S742, 2009

Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. Journal of Neurology Neurosurgery and Psychiatry 79(12): 1331-1338, 2008

Detection of cerebral amyloid angiopathy by 3-T magnetic resonance imaging and amyloid positron emission tomography in a patient with subcortical ischaemic vascular dementia. Psychogeriatrics 17(1): 70-72, 2017

Amyloid deposition in semantic dementia: a positron emission tomography study. International Journal of Geriatric Psychiatry 31(9): 1064-1074, 2016

Visualization of amyloid with positron emission tomography. Useful improvement in the diagnosis of dementia?. Der Nervenarzt 81(5): 602-606, 2010

Flutemetamol (18F): a β-amyloid positron emission tomography tracer for Alzheimer's and dementia diagnosis. Drugs of Today 50(3): 219-229, 2014

Amyloid positron-emission-tomography with [ 18  F]-florbetaben in the diagnostic workup of dementia patients. Der Nervenarzt 88(2): 156-161, 2017

Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography. Brain 134(Pt 6): 1647-1657, 2011

Clinical Applications of Positron Emission Tomography for Neurosurgery(5)Application of Positron Emission Tomography Molecular Imaging in the Diagnosis of Dementia Diseases. No Shinkei Geka. Neurological Surgery 45(12): 1109-1119, 2017

The impact of β-amyloid positron emission tomography on the diagnostic and treatment decisions of dementia experts. Neurodegenerative Disease Management 7(2): 107-117, 2017

Extremely Low Prevalence of Amyloid Positron Emission Tomography Positivity in Parkinson's Disease without Dementia. European Neurology 77(5-6): 231-237, 2017

Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. Alzheimer's Research and Therapy 10(1): 72, 2018

Amyloid-Beta Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia. Movement Disorders Clinical Practice 3(4): 367-375, 2016

Post-Mortem evaluation of amyloid-dopamine terminal positron emission tomography dementia classifications. Annals of Neurology 78(5): 824-830, 2015

Incidental Global Hypometabolism in the Brain of Patient with AIDS-related Dementia Seen on 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. Indian Journal of Nuclear Medicine 33(1): 73-75, 2018